Natalie Sacks
Director/Board Member bei CARIBOU BIOSCIENCES, INC.
Vermögen: 104 951 $ am 31.03.2024
Profil
Natalie R.
Sacks currently works at Caribou Biosciences, Inc., as Independent Director from 2018 and STipe Therapeutics ApS, as Director from 2020.
Dr. Sacks also formerly worked at Zymeworks BC, Inc., as Independent Director, Zymeworks, Inc., as Director from 2017 to 2023, Cell Genesys, Inc., as Vice President-Clinical Development from 2002 to 2009, Onyx Pharmaceuticals, Inc., as Vice President-Clinical Development from 2011 to 2014, Exelixis, Inc., as Vice President-Clinical Research from 2009 to 2011, Aduro BioTech, Inc., as Chief Medical Officer from 2016 to 2018, The University of California, San Francisco, as Assistant Clinical Professor from 2003 to 2016, and Harpoon Therapeutics, Inc., as Chief Medical Officer from 2018 to 2022.
Dr. Sacks received her undergraduate degree from Bryn Mawr College, graduate degree from Harvard T.H.
Chan School of Public Health, and doctorate degree from Perelman School of Medicine.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 07.01.2024 | 4 575 ( 0,02% ) | 104 951 $ | 29.02.2024 | |
| 20.02.2024 | 0 ( -.--% ) | - $ | 31.03.2024 |
Aktive Positionen von Natalie Sacks
| Unternehmen | Position | Beginn |
|---|---|---|
| CARIBOU BIOSCIENCES, INC. | Director/Board Member | 01.05.2018 |
STipe Therapeutics ApS
 STipe Therapeutics ApS Pharmaceuticals: MajorHealth Technology STipe Therapeutics ApS operates as a biotechnology company. It specializes in the immune-oncology field, pioneer therapies using a novel aspect of the stimulator of interferon genes (STING) Pathway to target cancer. The company was founded in 2018 and is headquartered in Denmark. | Director/Board Member | 01.04.2020 |
Ehemalige bekannte Positionen von Natalie Sacks
| Unternehmen | Position | Ende |
|---|---|---|
| ZYMEWORKS INC. | Director/Board Member | 30.06.2023 |
| HARPOON THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01.06.2022 |
| CHINOOK THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01.09.2018 |
| The University of California, San Francisco | Corporate Officer/Principal | 01.01.2016 |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Chief Tech/Sci/R&D Officer | 01.01.2014 |
Ausbildung von Natalie Sacks
| Bryn Mawr College | Undergraduate Degree |
| Harvard T.H. Chan School of Public Health | Graduate Degree |
| Perelman School of Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| EXELIXIS, INC. | Health Technology |
| CARIBOU BIOSCIENCES, INC. | Health Technology |
| HARPOON THERAPEUTICS, INC. | Health Technology |
| ZYMEWORKS INC. | Health Technology |
| Private Unternehmen | 5 |
|---|---|
Cell Genesys, Inc.
 Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Health Technology |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |
Zymeworks BC, Inc.
 Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | Health Technology |
Aduro BioTech, Inc.
 Aduro BioTech, Inc. Pharmaceuticals: MajorHealth Technology Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA. | Health Technology |
STipe Therapeutics ApS
STipe Therapeutics ApS Pharmaceuticals: MajorHealth Technology STipe Therapeutics ApS operates as a biotechnology company. It specializes in the immune-oncology field, pioneer therapies using a novel aspect of the stimulator of interferon genes (STING) Pathway to target cancer. The company was founded in 2018 and is headquartered in Denmark. | Health Technology |
